Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives

European Journal of Medicinal Chemistry

Volumn 101, Issue , 2015, Pages 236-244

  Pibiri, Ivana ^a,b   Lentini, Laura ^a   Melfi, Raffaella ^a   Gallucci, Giulia ^a   Pace, Andrea ^a,b   Spinello, Angelo ^a   Barone, Giampaolo ^a,b   Di Leonardo, Aldo ^a,c  

^a UNIVERSITY OF PALERMO   (Italy)

^b Istituto Euro Mediterraneo di Scienza e Tecnologia IEMEST   (Italy)

^c Centro di OncoBiologia Sperimentale (COBS)   (Italy)

Author keywords

CFTR gene; Cystic fibrosis; Fluorinated oxadiazole; Green fluorescent protein; Nonsense mutation; PTCs readthrough

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FLUORINE; MESSENGER RNA; CFTR PROTEIN, HUMAN; OXADIAZOLE DERIVATIVE; STOP CODON;

ARTICLE; CFTR GENE; CYSTIC FIBROSIS; FEMALE; FLUC GENE; GENE; GENETIC CODE; H2BGFP GENE; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; NONSENSE MUTATION; PLASMID; PROTEIN EXPRESSION; STOP CODON; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HELA CELL LINE; MUTATION; RNA TRANSLATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL CULTURE;

CODON, NONSENSE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HUMANS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; MUTATION; OXADIAZOLES; PEPTIDE CHAIN ELONGATION, TRANSLATIONAL; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84934763984     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2015.06.038     Document Type: Article

References (53)

1. S. Kervestin, A. Jacobson, NMD: a multifaceted response to premature translational termination, Nat. Rev. Mol. Cell. Biol. 13 (2012) 700-712.
2. J.A. Loudon, Cancer: a novel "no-nonsense" approach to treatment, Oncol. Res. 19 (2010) 55-66.
3. J. Karijolich, I.-T. Yu, Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (Review), Int. J. Mol. Med. 34 (2014) 355-362.
4. S.W. Peltz, M. Morsy, E.M. Welch, A. Jacobson, Ataluren as an agent for therapeutic nonsense suppression, Annu. Rev. Med. 64 (2013) 407-425.
5. S.M. Rowe, S. Miller, E.J. Sorscher, Cystic fibrosis, N. Engl. J. Med. 352 (2005) 1992-2001.
6. J.F. Burke, A.E. Mogg, Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin, Nucleic Acids Res. 13 (1985) 6265-6272.
7. M. Manuvakhova, K. Keeling, D.M. Bedwell, Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system, RNA 6 (2000) 1044-1055.
8. T. Hermann, Aminoglycoside antibiotics: old drugs and new therapeutic approaches, Cell. Mol. Life Sci. 64 (2007) 1841-1852.
9. K.M. Keeling, D.A. Brooks, J.J. Hopwood, P. Li, J.N. Thompson, D.M. Bedwell, Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation, Hum. Mol. Genet. 10 (2001) 291-299.
10. D.M. Bedwell, A. Kaenjak, D.J. Benos, Z. Bebok, J.K. Bubien, J. Hong, A. Tousson, J.P. Clancy, E.J. Sorscher, Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line, Nat. Med. 3 (1997) 1280-1284.
11. A. Prayle, A.R. Smyth, Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity, Curr. Opin. Pulm. Med. 16 (2010) 604-610.
12. M. Du, X. Liu, E.M. Welch, S. Hirawat, S.W. Peltz, D.M. Bedwell, PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 2064-2069.
13. E. Kerem, Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr. Opin. Pulm. Med. 10 (2004) 547-552.
14. E.M. Welch, E.R. Barton, J. Zhuo, Y. Tomizawa, W.J. Friesen, P. Trifillis, S. Paushkin, M. Patel, C.R. Trotta, S. Hwang, R.G. Wilde, G. Karp, J. Takasugi, G. Chen, S. Jones, H. Ren, Y.C. Moon, D. Corson, A.A. Turpoff, J.A. Campbell, M.M. Conn, A. Khan, N.G. Almstead, J. Hedrick, A. Mollin, N. Risher, M. Weetall, S. Yeh, A.A. Branstrom, J.M. Colacino, J. Babiak, W.D. Ju, S. Hirawat, V.J. Northcutt, L.L. Miller, P. Spatrick, F. He, M. Kawana, H. Feng, A. Jacobson, S.W. Peltz, H.L. Sweeney, PTC124 targets genetic disorders caused by nonsense mutations, Nature 447 (2007) 87-91.
15. E. Kerem, S. Hirawat, S. Armoni, Y. Yaakov, D. Shoseyov, M. Cohen, M. Nissim-Rafinia, H. Blau, J. Rivlin, M. Aviram, G.L. Elfring, V.J. Northcutt, L.L. Miller, B. Kerem, M. Wilschanski, Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial, Lancet 372 (2008) 719-727.
16. D.S. Auld, N. Thorne, W.F. Maguire, J. Inglese, Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 3585-3590.
17. P.K. Dranchak, E. Di Pietro, A. Snowden, N. Oesch, N.E. Braverman, S.J. Steinberg, J.G. Hacia, Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations, J. Cell. Biochem. 112 (2011) 1250-1258.
18. S.C. Harmer, J.S. Mohal, D. Kemp, A. Tinker, Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel, Biochem. J. 443 (2012) 635-642.
19. S.P. McElroy, T. Nomura, L.S. Torrie, E. Warbrick, U. Gartner, G. Wood, W.H. McLean, A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays, PLoS Biol. 11 (2013) e1001593.
20. C. Sarkar, Z. Zhang, A.B. Mukherjee, Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients, Mol. Genet. Metab. 104 (2011) 338-345.
21. T. Goldmann, N. Overlack, F. Moller, V. Belakhov, M. van Wyk, T. Baasov, U. Wolfrum, K. Nagel-Wolfrum, A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation, EMBO Mol. Med. 4 (2012) 1186-1199.
22. Y. Zhou, Q. Jiang, S. Takahagi, C. Shao, J. Uitto, Premature termination codon readthrough in the ABCC6 gene: potential treatment for pseudoxanthoma elasticum, J. Invest. Dermatol. 133 (2013) 2672-2677.
23. C. Kuschal, J.J. DiGiovanna, S.G. Khan, R.A. Gatti, K.A. Kraemer, Repair of UV photolesions in xeroderma pigmentosum group C cells induced by translational readthrough of premature termination codons, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 19483-19488.
24. M. Li, M. Andersson-Lendahl, T. Sejersen, A. Arner, Muscle dysfunction and structural defects of dystrophin-null sapje mutant zebrafish larvae are rescued by ataluren treatment, FASEB J. 28 (2014) 1593-1599.
25. C.Y. Gregory-Evans, X. Wang, K.M. Wasan, J. Zhao, A.L. Metcalfe, K. Gregory-Evans, Postnatal manipulation of Pax6 dosage reverses congenital tissue malformation defects, J. Clin. Invest. 124 (2014) 111-116.
26. L. Lentini, R. Melfi, A. Di Leonardo, A. Spinello, G. Barone, A. Pace, A. Palumbo Piccionello, I. Pibiri, Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay, Mol. Pharm. 11 (2014) 653-664.
27. N. Thorne, D.S. Auld, J. Inglese, Apparent activity in high-throughput screening: origins of compound-dependent assay interference, Curr. Opin. Chem. Biol. 14 (2010) 315-324.
28. N. Thorne, J. Inglese, D.S. Auld, Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology, Chem. Biol. 17 (2010) 646-657.
29. G.M. Karp, S. Hwang, G. Chen, N.G. Almstead, Y.-C. Moon 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease. U. S. Pat. Appl. Publ. 2006 US6992096B2.
30. R.M. Srivastava, M.N. Ramos, L.M. Mendes e Silva, Synthesis, spectroscopic studies and molecular orbital calculations of O-acylbenzamidoximes, Gazz. Chim. Ital. 113 (1983) 845-850.
31. P.K. Gupta, M.K. Hussain, M. Asad, R. Kant, R. Mahar, S.K. Shukla, K. Hajela, Metal-free tandem approach to structurally diverse N-heterocycles: synthesis of 1,2,4-oxadiazoles and pyrimidinones, New J. Chem. 38 (2014) 3062-3070.
32. T. Kanda, K.F. Sullivan, G.M. Wahl, Histone-GFP fusion protein enables sensitive analysis of chromosome dynamics in living mammalian cells, Curr. Biol. 8 (1998) 377-385.
33. L. Lentini, A. Amato, T. Schillaci, L. Insalaco, A. Di Leonardo, Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells, Oncol. Res. 17 (2008) 115-125.
34. C. Ferretti, P. Totta, M. Fiore, M. Mattiuzzo, T. Schillaci, R. Ricordy, A. Di Leonardo, F. Degrassi, Expression of the kinetochore protein Hec1 during the cell cycle in normal and cancer cells and its regulation by the pRb pathway, Cell Cycle 9 (2010) 4174-4182.
35. A.W. Sousa Da Silva, W.F. Vranken, E.D. Laue, ACPYPE - Antechamber python parser interface, BMC Res. Notes 5 (2012) 367.
36. J.M. Wang, W. Wang, P.A. Kollman, D.A. Case, Automatic atom type and bond type perception in molecular mechanical calculations, J. Mol. Graph. Model. 25 (2006) 247-260.
37. J.M. Wang, R.M.Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and testing of a general amber force field, J. Comput. Chem. 25 (2004) 1157-1174.
38. B. Hess, C. Kutzner, D. van der Spoel, E. Lindahl, GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation, J. Chem. Theory Comput. 4 (2008) 435-447.
39. D. Van der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, H.J.C. Berendsen, GROMACS: fast, flexible, and free, J. Comput. Chem. 26 (2005) 1701-1718.
40. A. Perez, I. Marchan, D. Svozil, J. Sponer, T.E. Cheatham, C.A. Laughton, M. Orozco, Refinement of the AMBER force field for nucleic acids: improving the description of alpha/gamma conformers, Biophys. J. 92 (2007) 3817-3829.
41. A.T. Guy, T.J. Piggot, S. Khalid, Single-stranded DNA within nanopores: conformational dynamics and implications for sequencing; a molecular dynamics simulation study, Biophys. J. 103 (2012) 1028-1036.
42. R. Kumari, R. Kumar, Open Source Drug Discovery Consortium; Lynn, A. g-mmpbsa - a GROMACS tool for high-throughput MM-PBSA calculations, J. Chem. Inf. Model. 54 (2014) 1951-1962.
43. A. Pace, P. Pierro, The new era of 1,2,4-oxadiazoles, Org. Biomol. Chem. 7 (2009) 4337-4348.
44. C.G. Fortuna, C. Bonaccorso, A. Bulbarelli, G. Caltabiano, L. Rizzi, L. Goracci, G. Musumarra, A. Pace, A. Palumbo Piccionello, A. Guarcello, P. Pierro, E.A.C. Cocuzza, R. Musumeci, New linezolid-like 1,2,4-oxadiazoles active against Gram-positive multiresistant pathogens, Eur. J. Med. Chem. 1 (2013) 533-545.
45. A. Pace, S. Buscemi, N. Vivona, The synthesis of fluorinated heteroaromatic compounds. Part 1. Five-membered rings with more than two heteroatoms. A review, Org. Prep. Proc. Int. 37 (2005) 447-506.
46. S. Buscemi, A. Pace, A. Palumbo Piccionello, N. Vivona, Synthesis of fluorinated first generation starburst molecules containing a triethanolamine core and 1,2,4-oxadiazoles, J. Fluor. Chem. 127 (2006) 1601-1605.
47. 2+ sensors: synthesis and evaluation of a Tren-based starburst molecule containing fluorinated 1,2,4-Oxadiazoles, Eur. J. Org. Chem. (2010) 4549-4553.
48. A. Palumbo Piccionello, A. Guarcello, A. Calabrese, A. Pibiri, A. Pace, S. Buscemi, Synthesis of fluorinated oxadiazoles with gelation and oxygen storage ability, Org. Biomol. Chem. 10 (2012) 3044-3052.
49. F.S. Palumbo, M. Di Stefano, A. Palumbo Piccionello, C. Fiorica, G. Pitarresi, I. Pibiri, S. Buscemi, G. Giammona, Perfluorocarbon functionalized hyaluronic acid derivatives as oxygenating systems for cell culture, RSC Adv. 4 (2014) 22894-22901.
50. H.-L.R. Lee, J.P. Dougherty, Pharmaceutical therapies to recode nonsense mutations in inherited diseases, Pharmacol. Ther. 136 (2012) 227-266.
51. P.-I. Ho, K. Yue, P. Pandey, L. Breault, F. Harbinski, A.J. McBride, B. Webb, J. Narahari, N. Karassina, K.V. Wood, A. Hill, D.S. Auld, Reporter enzyme inhibitor study to aid assembly of orthogonal reporter gene assays, ACS Chem. Biol. 8 (2013) 1009-1017.
52. S.-W. Jang, C. Lopez-Anido, R. MacArthur, J. Svaren, J. Inglese, Identification of drug modulators targeting gene-dosage disease CMT1A, ACS Chem. Biol. 7 (2012) 1205-1213.
53. M. Shalev, J. Kondo, D. Kopelyanskiy, C.L. Jaffe, N. Adir, T. Baasov, Identification of the molecular attributes required for aminoglycoside activity against Leishmania, Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 13333-13338.